SBRT 2016

C O N C L U S I O N S  Clear dose effect relationship in stage I NSCLC and pulmonary metastases  Dose explains well high rates of local tumor control  Dose-response not different between primary NSCLC and pulmonary metastases  PTV encompassing dose >100Gy BED achieves >90% TCP  Total dose adapted to competing risk of death / distant progression  Fractionation adapted to risk of OAR toxicity

Matthias Guckenberger - ESTRO SBRT Course 2016 Athens

13.06.2016

28

/